切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2023, Vol. 16 ›› Issue (03) : 306 -311. doi: 10.3877/cma.j.issn.1674-6902.2023.03.002

论著

丹龙口服液治疗轻中度慢性阻塞性肺疾病急性加重期的多中心及前瞻性研究
廖玥, 王可, 秦江月, 吴艳秋, 陈俊, 汪涛, 文富强†(), 王浩†()   
  1. 610044　成都，四川大学华西医院呼吸病学研究室
    610044　成都，四川大学华西医院呼吸病学研究室；610044　成都，四川大学华西医院呼吸与危重症医学科
    610044　成都，四川大学华西医院呼吸与危重症医学科
  • 收稿日期:2022-12-29 出版日期:2023-06-25
  • 通信作者: 文富强, 王浩

Efficacy of Danlong oral liquid in treatment of mild-to-moderate acute exacerbation of chronic obstructive pulmonary disease: A multicenter, prospective, observational cohort study

Yue Liao, Ke Wang, Jiangyue Qin, Yanqiu Wu, Jun Chen, Tao Wang, Fuqiang Wen†(), Hao Wang†()   

  1. Division of Pulmonary Disease, State Key Laboratory of Biotherapy of China, and Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610044, China
    Division of Pulmonary Disease, State Key Laboratory of Biotherapy of China, and Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610044, China; Division of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610044, China.
    Division of Pulmonary Disease, Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610044, China.
  • Received:2022-12-29 Published:2023-06-25
  • Corresponding author: Fuqiang Wen, Hao Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

廖玥, 王可, 秦江月, 吴艳秋, 陈俊, 汪涛, 文富强, 王浩. 丹龙口服液治疗轻中度慢性阻塞性肺疾病急性加重期的多中心及前瞻性研究[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 306-311.

Yue Liao, Ke Wang, Jiangyue Qin, Yanqiu Wu, Jun Chen, Tao Wang, Fuqiang Wen, Hao Wang. Efficacy of Danlong oral liquid in treatment of mild-to-moderate acute exacerbation of chronic obstructive pulmonary disease: A multicenter, prospective, observational cohort study[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(03): 306-311.

目的

分析丹龙口服液(Danlong oral liquid, DOL)联合西药常规疗法对轻中度慢性阻塞性肺疾病急性加重(acute exacerbation of chronic obstructive pulmonary disease, AECOPD)的疗效和安全性。

方法

选择2019年8月至2020年12月招募的中国16家医院AECOPD患者395例，随访7 d。治疗期间使用丹龙口服液联合常规西医疗法患者297例为观察组，只接受常规西医疗法患者98例为对照组。比较两组患者的AECOPD相关症状评分、中医症候评分和血清中的炎症因子水平，探讨药物疗效及安全性。

结果

观察组慢性阻塞性肺疾病评估量表(CAT)评分降低值大于对照组(3.24±2.90 vs. 2.47±2.62)，P<0.05。观察组治疗前后的中医证候评分下降分数大于对照组(4.62±3.73 vs. 3.62±3.22)，P<0.05。治疗期间使用全身性糖皮质激素观察组4例(1.35%)和对照组3例(3.62%)(P>0.05)。观察组不良事件发生率为8.75%，对照组为4.1%(P>0.05)。

结论

丹龙口服液联合西医常规疗法能有效安全缓解轻中度AECOPD临床症状，提高患者生活质量。

关键词: 急性加重，肺疾病，慢性阻塞性, 丹龙口服液, 前瞻研究, 中医，中成药, 临床疗效
Objective

To analyze the therapeutic effect and safety of Danlong oral liquid(DOL) combined with conventional western medicine exacerbations of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Methods

A total of 395 patients with AECOPD were recruited from 16 hospitals in China from August 2019 to December 2020 and followed up for 7 days. 297 patients who received Danlong oral liquid combined with conventional Western medicine during treatment were the observation group, and 98 patients who only received conventional Western medicine were the control group. The AecopD-related symptom scores, TCM symptom scores and serum levels of inflammatory factors were compared between the two groups.

Results

The Chronic obstructive pulmonary Disease Assessment Scale (CAT) score reduction in the observation group was greater than that in the control group (3.24±2.90 vs. 2.47±2.62), P<0.05. The decrease of TCM syndrome score in the observation group before and after treatment was greater than that in the control group (4.62±3.73 vs. 3.62±3.22), P<0.05. Systemic glucocorticoids were used in 4 cases(1.35%) of observation group and 3 cases(3.62%) of control group during treatment (P>0.05). The incidence of adverse events was 8.75% in the observation group and 4.1% in the control group (P>0.05).

Conclusion

Danlong oral liquid combined with conventional western medicine can effectively and safely relieve the clinical symptoms and improve the quality of life of patients with mild to moderate AECOPD.

Key words: Acute exacerbation of chronic obstructive pulmonary disease, Danlong oral liquid, Observational cohort study, Traditional Chinese medicine, Chinese patent medicine, Clinical effectiveness
表1 两组临床资料比较[n(%)]
临床资料 观察组(n＝297) 对照组(n＝98) P值
吸烟史     0.144
既往吸烟，现已戒烟 177 (59.60) 50 (51.02) －
从不吸烟 120 (40.40) 48 (48.98) －
酗酒史     0.070
既往酗酒，现已戒酒 92 (30.98) 23 (23.47) －
从不酗酒 205 (69.02) 75 (76.53) －
共病史      
高血压 84(28.28) 25(25.51) 0.594
冠心病 43(14.48) 9(9.18) 0.179
哮喘 20(6.73) 7(7.14) 0.889
糖尿病 25(8.42) 12(12.24) 0.259
药物过敏史 30(10.10) 9(9.18) 0.792
过去3月发生过上呼吸道感染 128(43.10) 50(51.02) 0.172
过去3月接受过COPD药物治疗 235(79.12) 79(80.61) 0.918
过去3月接受过COPD非药物治疗 33(11.11) 8(8.16) 0.407
过去1年发生过AECOPD 256(86.20) 81(82.65) 0.390
过去1年发生AECOPD的平均次数 1.85±1.07 1.77±1.13 0.343
肺功能参数      
FEV1/FVC(%) 54.20±11.25 55.47±10.81 0.380
FEV1(L) 1.42±0.69 1.49±0.70 0.336
动脉血气      
PaO2(mmHg) 75.07±13.63 75.82±13.79 0.790
PaCO2(mmHg) 40.11±5.27 40.89±5.18 0.374
氧合指数(mmHg) 358.42±68.09 366.45±70.24 0.796
表2 两组西药常规治疗比较[n(%)]
治疗方法   观察组(n＝297) 对照组(n＝98) P值
三联治疗 ICS+LABA+LAMA 40(13.47) 9(9.18) 0.265
二联治疗 ICS+LABA 101(34.01) 40(40.82) 0.222
  LAMA+LABA 4(1.35) 4(4.08) 0.096
单药治疗 LAMA 42(14.14) 14(14.29) 0.972
  茶碱 30(10.1) 12(12.24) 0.551
其他a   167(56.23) 55(56.12) 0.985
表3 症状相关评分(±s)
评分依据 观察组(n＝297) 对照组(n＝98) P值
CAT评分      
治疗前 20.36±4.59 19.57±4.03 0.158
治疗后 17.13±5.09a 17.10±4.64a 0.884
治疗差值 3.24±2.90 2.47±2.62 0.010b
中医症候评分      
治疗前 13.78±3.95 13.27±3.56 0.317
治疗后 9.16±4.60a 9.64±4.18a 0.286
治疗差值 4.62±3.73 3.62±3.22 0.006b
中医症候疗效[n(%)]     0.0218b
显效 27(9.09) 7(7.14)  
有效 130(43.77) 31(31.63)  
BCSS评分      
治疗前 4.75±1.54 4.55±1.39 0.254
治疗后 3.26±1.48a 3.32±1.41a 0.566
治疗差值 1.49±1.4 1.23±1.31 0.060
mMRC评分      
治疗前 2.32±0.71 2.22±0.68 0.284
治疗后 1.91±0.76a 1.86±0.73a 0.573
治疗差值 0.4±0.59 0.37±0.58 0.460
表4 中医症候单项症状评估(±s)
组　别 例数 咳　嗽 咳　痰 喘　息 胸　闷
治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
观察组 297 2.72±1.13 1.83±1.07ab 2.42±1.00 1.54±1.07ab 2.86±1.23 2.01±1.26a 2.30±1.37 1.58±1.32a
对照组 98 2.63±0.98 2.02±0.97a 2.45±0.93 1.86±1.16a 2.71±1.12 1.98±1.20a 2.12±1.28 1.45±1.18a
组　别 例数 痰多色黄或白黏，咯痰不爽 发　烧 口渴喜冷饮 大便干结
治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
观察组 297 1.42±0.58 0.89±0.67ab 0 0 1.29±0.75 0.82±0.76a 0.77±0.78 0.49±0.73a
对照组 98 1.46±0.58 1.07±0.68a 0 0 1.15±0.63 0.8±0.72a 0.73±0.67 0.47±0.58a
图1 不同亚组人群四项症状相关评估比较；注：柱状图中数字代表该亚组分析集人数；*，**，***表示P<0.05
1
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2
Lim Sam, Lam David Chi-Leung, Muttalif Abdul Razak, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey[J]. Asia Pac Fam Med, 2015, 14(1): 4.
3
Ritchie1 Andrew I, Wedzicha Jadwiga A. Definition, Causes, Pathogenesis，and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
4
Lim Sam, Lam David Chi-Leung, Muttalif Abdul Razak, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey[J]. Asia Pac Fam Med, 2015, 14(1): 4.
5
Yao CaoYuan, Liu XiaoLi, Tang Ze. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2285-2290.
6
Hogea Stanca-Patricia, Tudorache Emanuela, Fildan Ariadna Petronela, et al. Risk factors of chronic obstructive pulmonary disease exacerbations[J]. Clin Respir J, 2020, 14(3): 183-197.
7
Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper[J]. Eur Respir J, 2004, 23(6): 932-946.
8
Crisafulli Ernesto, Barbeta Enric, Ielpo Antonella, et al. Management of severe acute exacerbations of COPD: an updated narrative review[J]. Multidiscip Respir Med, 2018, 13: 36.
9
Varol Yelda, Karakurt Zuhal, Çrak Ali Kadri, et al. Inappropriate Utilization of Antibiotics in COPD Exacerbations[J]. Turk Thorac J, 2020, 21(6): 397-403.
10
Huang Yinghong, Cai Tiange, Xia Xi, et al. Research advances in the intervention of inflammation and cancer by active ingredients of traditional chinese medicine[J]. J Pharm Pharm Sci, 2016, 19(1): 114-126.
11
Zou Ping. Traditional Chinese medicine, food therapy, and hypertension control: a narrative review of chinese literature[J]. Am J Chin Med, 2016, 44(8): 1579-1594.
12
刘　旻，刘贵颖，胡思源，等. 西药联合丹龙口服液治疗轻、中度支气管哮喘急性发作期(热哮证)的随机、双盲、对照、多中心临床试验[J]. 中国中西医结合杂志，2015, 35(5): 529-533.
13
Xue Beibei, Zhao Qingyang, Chen Di, et al. Network pharmacology combined with molecular docking and experimental verification reveals the bioactive components and potential targets of Danlong Dingchuan decoction against asthma[J]. Evid Based Complement Alternat Med, 2022, 2022: 7895271.
14
Fu Kaiqiang, Feng Chao, Shao Lingzhen, et al. Tanshinone ⅡA exhibits anti-inflammatory and antioxidative effects in LPS-stimulated bovine endometrial epithelial cells by activating the Nrf2 signaling pathway[J]. Res Vet Sci, 2021, 136: 220-226.
15
Wang Hua, Zhong Lin, Mi Shaohua, et al. TanshinoneⅡA prevents platelet activation and down-regulates CD36 and MKK4/JNK2 signaling pathway[J]. BMC Cardiovasc Disord, 2020, 20(1): 81.
16
Li Xing, Luo Dan, Hou Yu, et al. Sodium tanshinone ⅡA Silate exerts microcirculation protective effects against spinal cord injury in vitro and in vivo[J]. Oxid Med Cell Longev, 2020, 2020: 3949575.
17
Sui Hua, Zhao Jihui, Zhou Lihong, et al. Tanshinone ⅡA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1αin hypoxic microenvironments in human colorectal cancer[J]. Cancer Lett, 2017, 403: 86-97.
18
邓桃妹，彭　灿，彭代银，等. 甘草化学成分和药理作用研究进展及质量标志物的探讨[J]. 中国中药杂志，2021, 46(11): 2660-2676.
19
Li Shuyu, Yang Qixin, Chen Feilong, et al. The antifibrotic effect of pheretima protein is mediated by the TGF-β1/Smad2/3 pathway and attenuates inflammation in bleomycin-induced idiopathic pulmonary fibrosis[J]. J Ethnopharmacol, 2022, 286: 114901.
20
Nile Shivraj Hariram, Su Jiajia, Wu Die, et al. Fritillaria thunbergii Miq. (Zhe Beimu): A review on its traditional uses, phytochemical profile and pharmacological properties[J]. Food Chem Toxicol, 2021, 153: 112289.
21
Yang Nan, Patil Sangita, Zhuge Jian, et al. Glycyrrhiza uralensis flavonoids present in anti-asthma formula, ASHMI, inhibit memory Th2 responses in vitro and in vivo[J]. Phytother Res, 2013, 27(9): 1381-1391.
22
Qiu Chenyu, Zhang Tingting, Zhang Wenxin, et al. Licochalcone A inhibits the proliferation of human lung cancer cell lines A549 and H460 by inducing G2/M cell cycle arrest and ER stress[J]. Int J Mol Sci, 2017, 18(8): 1761.
23
Jayaprakasam Bolleddula, Yang Nan, Wen Ming-Chun, et al. Constituents of the anti-asthma herbal formula ASHMI(TM) synergistically inhibit IL-4 and IL-5 secretion by murine Th2 memory cells, and eotaxin by human lung fibroblasts in vitro[J]. J Integr Med, 2013, 11(3): 195-205.
24
Singh Dave, Agusti Alvar, Anzueto Antonio, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019[J]. Eur Respir J, 2019, 53(5): 1900164.
25
Karloh Manuela, Mayer Anamaria Fleig, Maurici Rosemeri, et al. The COPD assessment test: what do we know so far: A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages[J]. Chest, 2016, 149(2): 413-425.
26
黄　蓓．《证候类中药新药临床研究技术指导原则》发布[J]．中医药管理杂志，2018, 26(21): 107.
27
Lv Linhua, Zheng Jinping, Zhang Ying, et al. Respiratory nursing care with Angong Niuhuang pill for patients with chronic obstructive pulmonary disease following cardiac surgery[J]. Jpn J Nurs Sci, 2021, 18(1): e12344.
28
Zhao Hui, Xiong Wei-hong, Zhao Xin, et al. Development and evaluation of a traditional Chinese medicine syndrome questionnaire for measuring sub-optimal health status in China[J]. J Tradit Chin Med, 2012, 32(2): 129-136.
29
Jin Jin, Zhang Hongchun, Li Demin, et al. Effectiveness of Xin Jia Xuan Bai Cheng Qi decoction in treating acute exacerbation of chronic obstructive pulmonary disease: study protocol for a multicentre, randomised, controlled trial[J]. BMJ Open, 2019, 9(11): e030249.
30
Leidy Nancy Kline, Rennard Stephen I, Schmier Jordana, et al. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation[J]. Chest, 2003, 124(6): 2182-2191.
31
Cazzola Mario, Hanania Nicola Alexander, MacNee William, et al. A review of the most common patient-reported outcomes in COPD-revisiting current knowledge and estimating future challenges[J]. Int J Chron Obstruct Pulmon Dis, 2015，10: 725-738.
32
Chen Lihua, Li Dongxun, Zhang Guosong, et al. Pharmacokinetics, tissue distribution and excretion of peimisine in rats assessed by liquid chromatography-tandem mass spectrometry[J]. Arch Pharm Res, 2015, 38(6): 1138-1146.
33
Liang Zhitao, Zhang Jian, Wong Lailai, et al. Characterization of secondary metabolites from the raphides of calcium oxalate contained in three araceae family plants using laser microdissection and ultra-high performance liquid chromatography-quadrupole/time of flight-mass spectrometry[J]. Eur J Mass Spectrom (Chichester), 2013, 19(3): 195-210.
34
Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2000, 161(5): 1608-1613.
35
Ren Jun-Ling, Zhang Ai-Hua, Wang Xi-Jun. Traditional Chinese medicine for COVID-19 treatment[J]. Pharmacol Res, 2020, 155: 104743.
36
Huang Kai, Zhang Pan, Zhang Zhenghao, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms[J]. Pharmacol Ther, 2021, 225: 107843.
37
花照泉，畅亦杰. 益气清肺汤联合标准桃金娘油治疗AECOPD的临床疗效研究[J]. 中国中药杂志，2013, 38(3): 440-442.
38
Liet Jean-Michel, Ducruet Thierry, Gupta Vineet, et al. Heliox inhalation therapy for bronchiolitis in infants[J]. Cochrane Database Syst Rev, 2015, 2015(9): Cd006915.
39
胡光煦，汪　良，池卫明，等. 痰热清注射液联合西医常规治疗对慢性阻塞性肺疾病急性加重期患者疗效及红细胞免疫功能影响[J]. 药物流行病学杂志，2019, 28(5): 283-287.
[1] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[2] 边亚礼, 杨艳双, 何新霞. 清咳平喘颗粒联合左氧氟沙星对社区获得性肺炎的疗效分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 254-256.
[3] 刘有才, 张义君, 赵欣磊, 周家玄. Endobutton带袢钛板与钩钢板治疗肩锁关节脱位病例的疗效比较[J]. 中华肩肘外科电子杂志, 2023, 11(03): 212-217.
[4] 黄瑶, 袁滨, 束昊, 王磊, 孙鲁宁. 关节镜下带线锚钉修补术治疗Ⅴ型SLAP损伤临床观察[J]. 中华肩肘外科电子杂志, 2023, 11(03): 218-223.
[5] 张琳袁, 吴佳俊, 崔煦, 沈超, 付备刚, 崔崟, 王秀会, 蔡攀. 大结节解剖钢板与PHILOS内固定治疗伴肩关节脱位的Mutch I/II型肱骨大结节骨折的疗效差异[J]. 中华肩肘外科电子杂志, 2023, 11(02): 139-145.
[6] 姜里蛟, 张峰, 周玉萍. 多学科诊疗模式救治老年急性非静脉曲张性上消化道大出血患者的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 520-524.
[7] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[8] 张景旭, 李德舫, 由上可, 张玉田. 贝伐珠单抗与安罗替尼联合奥沙利铂治疗晚期直肠癌的临床疗效[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 289-293.
[9] 盛静, 梅勇, 夏佩, 王晓林. 乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 317-321.
[10] 董骏, 吴芳芳. mFOLFOX6与FOLFOX4化疗方案治疗直肠癌的临床疗效及安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 236-240.
[11] 赵军, 李超杰, 李佳. 雷贝拉唑联合康复新液对治疗幽门螺杆菌阳性的十二指肠溃疡的疗效[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 254-258.
[12] 于晓东, 李德华, 高山, 徐鑫. 理中汤加味联合美沙拉嗪治疗轻度活动期克罗恩病的临床观察[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 199-202.
[13] 李莹倩, 李华山. 基于真实世界的完全性直肠脱垂治疗方式评价[J]. 中华临床医师杂志(电子版), 2023, 17(06): 700-705.
[14] 范勇, 张利昉, 杨美琳. 改良经口内镜下贲门缩窄术治疗胃食管反流病效果分析[J]. 中华胃食管反流病电子杂志, 2023, 10(02): 65-68.
[15] 穆曼娜, 胡莹清, 李远, 张勇军, 胡细玲, 林倍思, 刘德昭. 氯雷他定联用普瑞巴林治疗2型糖尿病皮肤瘙痒症的临床效果评价[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 114-119.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号